[go: up one dir, main page]

EP1608387A2 - COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS - Google Patents

COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS

Info

Publication number
EP1608387A2
EP1608387A2 EP04724578A EP04724578A EP1608387A2 EP 1608387 A2 EP1608387 A2 EP 1608387A2 EP 04724578 A EP04724578 A EP 04724578A EP 04724578 A EP04724578 A EP 04724578A EP 1608387 A2 EP1608387 A2 EP 1608387A2
Authority
EP
European Patent Office
Prior art keywords
diseases
active ingredient
oil
treatment
ingredient combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04724578A
Other languages
German (de)
English (en)
Inventor
Egon Koch
Karl-Heinz Stumpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Bioplanta Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplanta Arzneimittel GmbH filed Critical Bioplanta Arzneimittel GmbH
Publication of EP1608387A2 publication Critical patent/EP1608387A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to active ingredient combinations of ⁇ 3-fatty acid-containing oils with polyphenolic-containing plant extracts and their use for the treatment of inflammatory and / or immunological and metabolic diseases and other disorders.
  • ⁇ 3 fatty acids are responsible for the • disease process in chronic inflammatory and / or immunological diseases, such as ⁇ .
  • B. favorably affect atherosclerosis, coronary heart disease, rheumatoid arthritis, psoriasis etc. It is also reported that these fatty acids have preventive and protective effects in fat metabolism disorders or diabetes and are therefore suitable for the treatment of vascular and neurological disorders, such as those that occur in these diseases.
  • ⁇ 3 fatty acids With a lack of ⁇ 3 fatty acids in the diet, visual and central nervous disorders as well as hemorrhagic dermatitis, growth disorders and delayed wound healing were observed. Since the mammal organism is unable to synthesize these compounds itself, it is dependent on food.
  • ⁇ 3 fatty acids prevent the formation of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid by displacing this fatty acid from its binding in the SN2 position of phospholipids in the cell membranes.
  • Polyunsaturated fatty acids such as B. ⁇ -linolenic acid, eicosapentaenoic acid or docosahexaenoic acid are extremely sensitive to oxidation. The incorporation such fatty acids or their secondary products in cellular membranes therefore increases the organism's need for antioxidants.
  • polyphenols includes simple phenol carboxylic acids such as. As gentisic acid, protocatechic acid, gallic acid or caffeic acid, flavones such as. As camphor oil, quercetin, myricetin, isorhamnetin, naringenin, 6-prenylnaringenin, 8-prenylnaringenin, isoxanthohumol and their glycosides, chalcones such as. B. xanthohumol, isoflavones such as. B.
  • anthocyanins such as. As pelargonidine, cyanidine, malvidin or delphinidine, tanning agents such as. B. catechin and epicatechin, their oligomers and polymers and lignans. All of these compounds are reducing agents and, along with other antioxidant substances, e.g. As vitamins C and E, to protect the body against oxidative stress. Oxidative stress is a condition in the body in which the formation of oxidants and free radicals exceeds the body's ability to inactivate these substances. As a result, proteins, DNA and lipids as well as cell membranes and other structural elements are damaged.
  • oxidation products are involved in the development of common diseases such as atherosclerosis, chronic inflammation, cancer or diabetes and accelerate the aging process.
  • the amount of free radicals depends on lifestyle (diet, smoking, exercise) and is influenced by existing illnesses (eg hypercholesterolemia, diabetes).
  • a particularly rich source of oxygen radicals are e.g. B. neutrophilic granulocytes, which release these compounds in inflammatory reactions. Since endogenously formed molecules or enzymes with an antioxidative effect cannot be influenced in their concentration or activity by exogenous measures, the intake of antioxidants via nutrition is of crucial importance.
  • the object of the present invention is to provide means for the prevention and treatment of inflammatory and immunological diseases and of tumor disorders.
  • This object is achieved by a combination of active ingredients comprising at least one oil containing ⁇ 3 fatty acid and at least one plant extract containing polyphenol, which at the same time compensates for a deficiency in ⁇ 3 fatty acids and antioxidative polyphenols, prevents such a deficiency or an increased need for these substances in the case of inflammatory and / or immunological and metabolic diseases and tumor disorders.
  • this combination of active substances counteracts two important factors involved in the pathogenesis of inflammatory reactions and metabolic diseases. It also has the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative action of the polyphenols and / or vitamins both during storage and after incorporation in cell membranes.
  • a preferred ⁇ 3 fatty acid is ⁇ -linolenic acid, which is contained, for example, about 50-60% in the oil from the seeds of Perilla frutescens (Perillaöll). For this reason, perilla oil is a preferred ⁇ 3 fatty acid oil.
  • suitable oils include borage oil, evening primrose seed oil, fish oil, currant seed oil and linseed oil.
  • Preferred polyphenol-containing plant extracts are extracts from Aspalathus linearis, Crataegus species, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Paullinia cupana, Rubus fructicosus, Rubus idaeus, Tabebuia avellanedae, The obroma cacao, Vaccinium myrtilla and Vitis vinifer.
  • the polyphenol-containing plant extract preferably contains at least 15% by weight of polyphenols, based on the dry extract.
  • Active substance combinations which contain one of the following combinations are preferred: extract from Vitis vinifera and perilla seed oil, extract from Vaccinium myrtillus and linseed oil, extract from ginkgo biloba and linseed oil, extract from crataegus and borage oil, extract from Aspalathus linearis and borage oil, extract from Theobroma cacao and evening primrose seed oil, extract from Tabebuia avellanedae and evening primrose seed oil, extract from fish oil, extract from Hypericumupulus and undatum Fish oil, extract from Paullinia cupana and currant kernel oil, extract from Rubus idaeus and currant kernel oil, extract from Rubus fructicosus and perilla seed oil, extract from Aspalathus linearis and perilla seed oil as well as extract from Humulus lupulus and perilla seed oil.
  • the extracts can be prepared in a variable composition with solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
  • solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and mixtures thereof at temperatures from room temperatures to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or elevated pressure be preserved.
  • further concentration steps can be carried out, e.g. B. liquid-liquid distribution with z. B. 1-butanol water or ethyl acetate / water, adsorption-desorption on ion exchanger, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc.
  • the further processing to dry extracts is
  • the active substance combinations according to the invention can be used for the treatment, for the support of the treatment or for the prophylaxis of inflammatory and / or immunological and metabolic diseases and other disorders, such as, for. B. rheumatoid arthritis, polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia, of chronic bowel diseases, such as. B. ulcerative colitis or Crohn's disease, as well as polyneuropathies, retinopathies, cerebral and peripheral arterial circulatory disorders, psychiatric disorders such as. B. depression, schizophrenia, bipolar disorder, and tumor diseases.
  • rheumatoid arthritis polyarthritis, synovitis, acne, neurodermatitis, psoriasis, asthma, hay fever, atherosclerosis, coronary heart disease or arrhythmia
  • chronic bowel diseases such as. B. ulcerative colitis or Crohn's disease,
  • the active ingredient combination according to the invention can be in the form of a dietetic food or pharmaceutical.
  • the active substance combinations according to the invention are preferably administered as part of a balanced diet.
  • the drug combinations can additional components such.
  • B. Vitamin C and / or E are added to compensate for their deficiency or to ensure their increased need.
  • the active substance combinations according to the invention are well suited for filling into capsules.
  • other substances such as B. partially or fully hydrogenated vegetable oils, beeswax, lecithin, neutral oil, hard fat and highly disperse silicon dioxide can be added to the capsule filling compound in order to adjust the consistency of the mixtures and to prevent segregation of the liquid component and solid plant extract.
  • amphiphilic, surface-active substances and emulsifiers such as. B. Sorbitan monooleate can be added.
  • the plant extract is mixed with the oil (both according to the table below) and the flowable suspension obtained is filled into capsules using a suitable method.
  • ⁇ 3-fatty acid-containing oils and polyphenol-containing plant extracts described in the preceding examples are distinguished by the fact that they inhibit the synthesis of pro-inflammatory eicosanoids and the neutralization of free radicals. They also have the advantage that the oxidation-sensitive ⁇ 3 fatty acids are protected from degradation by the antioxidative effect of the polyphenols both during storage and after incorporation in cell membranes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des combinaisons de principes actifs d'huiles contenant des acides gras φ3 avec des extraits végétaux contenant des polyphénols et l'utilisation desdites combinaisons dans le traitement de maladies inflammatoires et/ou immunologiques et méboliques ainsi que d'autres affections.
EP04724578A 2003-04-02 2004-03-31 COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS Withdrawn EP1608387A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10315025 2003-04-02
DE10315025A DE10315025A1 (de) 2003-04-02 2003-04-02 Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung
PCT/EP2004/003401 WO2004087181A2 (fr) 2003-04-02 2004-03-31 Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons

Publications (1)

Publication Number Publication Date
EP1608387A2 true EP1608387A2 (fr) 2005-12-28

Family

ID=32980960

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04724578A Withdrawn EP1608387A2 (fr) 2003-04-02 2004-03-31 COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS

Country Status (7)

Country Link
EP (1) EP1608387A2 (fr)
BR (1) BRPI0409139A (fr)
CA (1) CA2521040A1 (fr)
DE (1) DE10315025A1 (fr)
MX (1) MXPA05010416A (fr)
RU (1) RU2005130342A (fr)
WO (1) WO2004087181A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1791393A (zh) * 2003-04-08 2006-06-21 麒麟麦酒株式会社 用于抑制或预防骨密度减少的组合物、食品和饮料
ATE423564T1 (de) * 2003-11-03 2009-03-15 Cortex Technology Aps Zusammensetzung für die kosmetische behandlung von altersbedingten dermatologischen symptomen
FR2885528A1 (fr) * 2005-05-13 2006-11-17 Persee Medica Composition utile pour traiter ou prevenir les troubles lies a un dereglement de l'horloge biologique
DE102005035864A1 (de) * 2005-07-30 2007-02-01 Beiersdorf Ag Verwendung von Xanthohumol und/oder Isoxanthohumol zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE102006033321A1 (de) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medizinische Verwendung von N-Phenylpropenoyl-Aminosäurederivaten und verwandten Verbindungen
FR2912918A1 (fr) * 2007-02-27 2008-08-29 Persee Medica Soc Par Actions Utilisation d'acides gras polyinsatures et de flavonoides en tant qu'agents actifs dans une composition pour la prevention et/ou le traitement des cephalees.
GB0719545D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719542D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719544D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
EP2133088A3 (fr) * 2008-06-09 2010-01-27 Nestec S.A. Rooibos et inflammation
EP2135616B1 (fr) * 2008-06-19 2016-05-04 Symrise AG Fruit d'airelle séché destiné à influencer l'état de l'intestin
WO2015154192A1 (fr) * 2014-04-11 2015-10-15 George Robertson Utilisation d'une composition contenant un flavonol, un flavonoïde et un acide gras dans le traitement de lésions oxydatives causées par un dysfonctionnement mitochondrial
CN109316535A (zh) * 2017-07-31 2019-02-12 格特生物制药（天津）有限公司 一种治疗鸡滑膜炎的中药组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0558901A (ja) * 1991-08-26 1993-03-09 Teikoku Hormone Mfg Co Ltd 骨吸収抑制因子およびその製造方法
FR2770974A1 (fr) * 1997-11-20 1999-05-21 Hatem Smaoui Nouveau complement nutritionnel a base de lycopene de tomate, d'acides gras r 3-6-9 et antioxydants primaires et secondaires
DE10315026A1 (de) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Zusammensetzungen enthaltend omega-3-fettsäurehaltige Öle und Pflanzenextrakte
DE10315027A1 (de) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Kapseln mit verzögerter Freisetzung des Kapselinhaltes zur oralen Verabreichung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIPER: "Diätische Interventionen mit Perilla-Öl und Rotweintrauben-Extrakt als ergängzende bilanzierte Diät bei Patienten mit atherosklerotischen Gefässerkrankungen und Bluthochdruck", ERNÄHRUNG UND MEDIZIN, vol. 20, 1 January 2005 (2005-01-01) - 1 January 2005 (2005-01-01), pages 20 - 26 *

Also Published As

Publication number Publication date
WO2004087181A2 (fr) 2004-10-14
WO2004087181A3 (fr) 2005-04-21
RU2005130342A (ru) 2006-03-27
BRPI0409139A (pt) 2006-03-28
MXPA05010416A (es) 2006-03-21
CA2521040A1 (fr) 2004-10-14
WO2004087181A8 (fr) 2004-12-29
DE10315025A1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
AT407821B (de) Mittel auf der basis von naturstoffen
ES2924255T3 (es) Extracto vegetal altamente concentrado en safranal, método de producción y usos del mismo
JP2018505866A (ja) マルチサプリメント組成物
EP1377273B1 (fr) Procede de production d'un concentre d'isoflavone
EP0295331A2 (fr) Utilisation de la vitamine E pour l'obtention des médicaments destinés à normaliser la coagulation sanguine dans la thérapie avec des acides gras hautement insaturés de type oméga 3
DE60027481T2 (de) Zusammensetzung zur Behandlung von chronischer venöser Insuffizienz mit einem Extrakt aus Blättern von roten Weinreben
EP1608387A2 (fr) COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS
DE602004006860T2 (de) Capsaicinoid enthaltende pharmazeutische zusammensetzung zur oralen verabreichung
KR960008289B1 (ko) 물함유 유기용매에 의하여 얻은 추출물을 함유하는 조성물 및 그 제조방법
CN105920476A (zh) 防治阿尔茨海默病中药组合物及其制备方法
EP1091659A1 (fr) Forme galenique orale
DE3504695A1 (de) Haarwuchsmittel
EP2485718A1 (fr) Utilisation d'une composition à base d' érémophilanolides
EP1305013A1 (fr) Preparation antioxydante protegeant contre les affections vasculaires et son utilisation
EP2282751B1 (fr) Combinaison d'extraits de plantes possédant une spécificité de compartiment et contenant un extrait de ginkgo biloba et de ginseng exerçant un effet tandem
EP1608386A1 (fr) Compositions qui comprennent des huiles contenant des acides gras omega-3 et des extraits vegetaux
EP1608345A1 (fr) Capsules pour administration orale a action retardee du contenu de la capsule
EP1541158B1 (fr) Composition antioxydante pour l'administration orale ou topique
JP2009196967A (ja) 血中多価不飽和脂肪酸相対量増加剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、可食性組成物及び動物用飼料
Chauhan et al. Review on nutritional composition, bioactive compounds and therapeutic properties of Hippophae rhamnoides L.(Sea Buckthorn)
DE102011052708A1 (de) Verfahren zum Schutz photolabiler Wirkstoffe
AU2021392316B2 (en) Eutectic matrix for nutraceutical compositions
EP4284405A1 (fr) <smallcaps/>? ? ?scutellaria? ? ? ? ?combinaisons d'extraits deavec des extraits de <ns3:i>citrus bergamia</ns3:i>?ou de <ns4:i>cynara cardunculus</ns4:i>?et formulations les contenant
EP2229168A1 (fr) Composition pharmaceutique pour le traitement du paludisme
DE202023103890U1 (de) Extrakt aus Amlafrüchten und selbigen beinhaltende Nährstoffzusammensetzung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050912

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RTI1 Title (correction)

Free format text: ACTIVE INGREDIENT COMBINATIONS OF PLANT OILS CONTAINING OMEGA3-FATTY ACIDS AND PLANT EXTRACTS CONTAINING POLYPHENOLS AND THE USE THEREOF

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DR. WILLMAR SCHWABE GMBH & CO. KG

17Q First examination report despatched

Effective date: 20070614

R17C First examination report despatched (corrected)

Effective date: 20100316

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151001